By Counterforce Health Team in Ocrevus (ocrelizumab) —

How to Get Ocrevus (ocrelizumab) Covered by Humana in Illinois: Prior Authorization, Appeals & Step Therapy

Answer Box: Getting Ocrevus Covered by Humana in Illinois

Ocrevus (ocrelizumab) requires prior authorization from Humana and is subject to step therapy requirements. You'll typically need to document failure or intolerance of preferred DMTs first. The medication is covered under Part B (medical benefit), not Part D. First step: Have your neurologist submit a prior authorization request with detailed MS diagnosis, prior DMT history, and medical necessity documentation. If denied, you have 65 days to appeal, with automatic external review by an Independent Review Organization if needed.

Table of Contents

  1. Plan Types & Coverage Implications
  2. Formulary Status & Tier Placement
  3. Prior Authorization & Step Therapy Requirements
  4. Specialty Pharmacy & Infusion Networks
  5. Cost-Share Dynamics
  6. Submission Process & Required Documentation
  7. Appeals Process in Illinois
  8. Common Denial Reasons & Solutions
  9. Patient Scripts & Templates
  10. FAQ

Plan Types & Coverage Implications

Humana offers several plan types in Illinois, and your specific coverage for Ocrevus depends on which type you have:

Medicare Advantage Plans: If you have a Humana Medicare Advantage plan, Ocrevus is covered under the Part B medical benefit, not Part D pharmacy benefit. This means you'll face coinsurance (typically 20% after meeting your annual deductible) rather than fixed copays.

Medicaid/Dual-Eligible Plans: Humana Gold Plus Integrated plans in Illinois follow both CMS and Illinois HFS requirements. Coverage rules may be more restrictive, with additional state-level utilization management.

Commercial Plans: Less common in Illinois, but if you have employer-sponsored Humana coverage, prior authorization requirements still apply with potentially different step therapy protocols.

Note: Regardless of plan type, Ocrevus infusions require in-network administration to avoid higher out-of-pocket costs.

Formulary Status & Tier Placement

Ocrevus is covered as a specialty medication under Humana's medical benefit rather than appearing on traditional pharmacy formulary tiers. According to Humana's 2025 coverage policies, the medication requires prior authorization and may be subject to step therapy protocols.

Alternative Agents on Formulary

Humana typically prefers these DMTs before approving Ocrevus:

  • Preferred injectables: Various interferon formulations and glatiramer acetate
  • Oral alternatives: Fingolimod (Gilenya), siponimod (Mayzent)
  • Other anti-CD20 agents: Kesimpta (ofatumumab) may be preferred in some cases

The specific preferred drug list can change annually, so always verify current requirements through Humana's provider portal.

Prior Authorization & Step Therapy Requirements

Coverage Requirements Table

Requirement Details Documentation Needed Source
Prior Authorization Required for all plans Complete PA form with clinical justification Humana PA Guidelines
Step Therapy Must try preferred DMTs first Records of prior DMT trials, failures, or contraindications 2025 Step Therapy List
MS Diagnosis Confirmed relapsing or primary progressive MS ICD-10 codes, MRI reports, clinical notes Policy requirement
Infusion Site In-network provider required Verify through provider directory Network requirement

Step Therapy Documentation

Your neurologist must provide evidence of:

  1. Diagnosis confirmation: Specific MS phenotype (RRMS, SPMS, or PPMS)
  2. Prior DMT history: Names, dates, duration of each therapy tried
  3. Treatment failures: Objective evidence like new relapses, MRI progression, or disabling side effects
  4. Medical necessity: Why Ocrevus is specifically needed over alternatives

Specialty Pharmacy & Infusion Networks

Ocrevus infusions must be administered through Humana's approved specialty pharmacy network. The medication is typically provided through:

  • Hospital outpatient infusion centers (most common)
  • Specialty infusion clinics
  • Neurologist office-based infusion (if properly equipped)
  • Home infusion services (when clinically appropriate)
Tip: Use Humana's provider directory or call member services to verify your preferred infusion site is in-network before scheduling treatment.

According to Humana's Illinois provider manual, coverage requires both the infusion site and administering physician to be in-network.

Cost-Share Dynamics

Medicare Advantage Cost Structure

For Humana Medicare Advantage members in Illinois:

  • Annual Part B deductible: $185 (2025)
  • Coinsurance: Typically 20% of Medicare-approved amount
  • Out-of-pocket maximum: Varies by plan (often $3,000-$8,000 annually)

Potential Cost-Saving Options

  • Genentech Copay Program: May reduce out-of-pocket costs for eligible patients
  • Patient assistance foundations: Organizations like The HealthWell Foundation offer MS-specific grants
  • State pharmaceutical assistance: Illinois residents may qualify for additional support programs

Note: This information is educational only and not financial advice. Verify current costs with Humana member services.

Submission Process & Required Documentation

Step-by-Step: Fastest Path to Approval

  1. Gather Documentation (Patient/Clinic)
    • Insurance cards and member ID
    • Complete MS diagnostic workup
    • Prior DMT trial records
    • Current MRI reports
  2. Complete Prior Authorization Form (Prescriber)
    • Submit through Humana provider portal
    • Include all required clinical documentation
    • Timeline: Submit 5-7 business days before planned infusion
  3. Track Submission Status (Clinic Staff)
    • Most decisions within 1 business day for electronic submissions
    • Follow up if no response within 48 hours
  4. Schedule Infusion (Patient)
    • Only after PA approval
    • Verify in-network status of infusion site
    • Confirm insurance authorization with facility
  5. Monitor for Approval (All Parties)
    • Humana commits to faster decisions through 2025 initiatives
    • Expedited review available for urgent cases

Required Clinical Documentation

Your neurologist's submission should include:

  • Diagnosis details: ICD-10 codes (G35 for MS), symptom history
  • Prior treatments: Complete DMT history with dates and outcomes
  • Imaging results: Recent MRI reports showing disease activity
  • Functional status: EDSS scores or other disability measures
  • Treatment rationale: Why Ocrevus is medically necessary

Appeals Process in Illinois

Illinois-Specific Appeal Timeline

Appeal Level Deadline to File Decision Timeline Who Decides
First Appeal (Humana) 65 calendar days 30 days standard, 72 hours expedited Humana internal review
External Review (IRO) Automatic after denial 30 days standard, 72 hours expedited Medicare-contracted Independent Review Entity
ALJ Hearing 60 days from IRO decision 90-180 days Administrative Law Judge

How to File an Appeal

Online: Through your MyHumana account portal Phone: Member services number on your insurance card
Mail/Fax: Address provided in denial letter

Important: Illinois residents have strong appeal rights under the Health Carrier External Review Act, but Medicare Advantage appeals follow federal Medicare timelines shown above.

For additional support, contact:

  • Illinois Department of Insurance: (877) 527-9431
  • Illinois Attorney General Health Care Helpline: (877) 305-5145

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
"Step therapy not completed" Document prior DMT failures Detailed treatment history with dates and outcomes
"Not medically necessary" Strengthen clinical justification Current MRI, disability scores, treatment goals
"Experimental/investigational" Cite FDA approval FDA labeling, clinical guidelines
"Quantity/frequency limits exceeded" Justify dosing schedule Manufacturer dosing guidelines, clinical rationale

Strengthening Your Appeal

When appealing a denial, include:

  1. Point-by-point rebuttal addressing each denial reason
  2. Current clinical evidence showing disease activity
  3. Peer-reviewed literature supporting Ocrevus use
  4. Specialist letter from your neurologist

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters and plan policies to create point-by-point rebuttals aligned with each payer's specific requirements.

Patient Scripts & Templates

Calling Humana Member Services

"Hi, I'm calling about prior authorization for Ocrevus for multiple sclerosis. My member ID is [number]. My neurologist submitted a PA request on [date]. Can you tell me the status and what additional information might be needed?"

Requesting Expedited Review

"My neurologist has determined that Ocrevus is medically necessary for my MS treatment, and any delay could worsen my condition. I'm requesting an expedited review of my prior authorization. What documentation do you need for expedited processing?"

Follow-up Email Template

"Dear [Insurance Representative],

I'm following up on prior authorization request #[number] for Ocrevus (ocrelizumab) submitted on [date]. Please confirm receipt and provide an expected decision timeline. If additional documentation is needed, please specify exactly what clinical information would support approval.

Thank you, [Name] Member ID: [number]"

FAQ

How long does Humana prior authorization take for Ocrevus in Illinois? Most electronic submissions receive decisions within 1 business day, with standard timeline up to 30 days. Humana has committed to reducing authorization times through 2025.

What if Ocrevus is considered non-formulary? As a Part B medical benefit, traditional formulary status doesn't apply. However, step therapy and prior authorization requirements still govern coverage.

Can I request an expedited appeal if my MS is worsening? Yes, expedited appeals are available when delays could seriously jeopardize your health. Both internal appeals and external reviews can be expedited with 72-hour decision timelines.

Does step therapy apply if I tried DMTs in another state? Yes, prior treatment history from any location counts toward step therapy requirements. Ensure your neurologist includes complete documentation of all prior therapies.

What happens if Humana denies my appeal? The case automatically goes to external review by an Independent Review Organization. This independent physician reviewer can overturn Humana's denial, making coverage mandatory.

Are there patient assistance programs for Ocrevus? Genentech offers copay assistance and patient support programs. Additionally, organizations like The HealthWell Foundation provide grants for MS treatments.

How do I find in-network infusion centers in Illinois? Use Humana's online provider directory or call member services. Verify both the facility and administering physician are in-network before scheduling.

What if I need Ocrevus but only have Part D coverage? Ocrevus infusions aren't covered under Part D. You'd need Part B coverage through Medicare Advantage or traditional Medicare plus Medigap.

This article provides educational information only and is not medical or legal advice. Coverage policies and requirements can change. For the most current information, consult your insurance plan documents and healthcare providers.

Need help with a complex appeal? Counterforce Health helps patients and clinicians turn insurance denials into successful appeals by creating targeted, evidence-backed submissions that address each payer's specific coverage criteria.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.